Banu Arun

24.7k total citations · 3 hit papers
260 papers, 11.5k citations indexed

About

Banu Arun is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Banu Arun has authored 260 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Genetics, 119 papers in Oncology and 108 papers in Cancer Research. Recurrent topics in Banu Arun's work include BRCA gene mutations in cancer (123 papers), Cancer Genomics and Diagnostics (66 papers) and Breast Cancer Treatment Studies (45 papers). Banu Arun is often cited by papers focused on BRCA gene mutations in cancer (123 papers), Cancer Genomics and Diagnostics (66 papers) and Breast Cancer Treatment Studies (45 papers). Banu Arun collaborates with scholars based in United States, United Kingdom and India. Banu Arun's co-authors include Gabriel N. Hortobágyi, Jennifer K. Litton, Vicente Valero, Daniel J. Booser, Lajos Pusztai, Angelica M. Gutierrez‐Barrera, Ayşegül A. Şahin, Massimo Cristofanilli, Kelly K. Hunt and Kristine Broglio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Banu Arun

250 papers receiving 11.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Nuhad K. Ibrahim, Daniel J. Booser et al. Journal of Clinical Oncology profile →
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

2017 768 citations Shiping Jiao, Weiya Xia et al. Clinical Cancer Research profile →
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

2015 512 citations Banu Arun et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Banu Arun United States	52	6.1k	3.9k	3.5k	3.3k	1.7k	260	11.5k
Ping Sun Canada	47	4.9k 0.8×	4.4k 1.1×	4.2k 1.2×	2.8k 0.8×	1.2k 0.7×	128	10.9k
Paul E. Goss United States	47	5.4k 0.9×	3.8k 1.0×	3.7k 1.1×	2.3k 0.7×	2.1k 1.2×	214	10.6k
Peggy L. Porter United States	60	7.5k 1.2×	3.9k 1.0×	2.0k 0.6×	4.1k 1.2×	1.7k 1.0×	140	13.3k
Jenny C. Chang United States	61	6.8k 1.1×	4.7k 1.2×	1.7k 0.5×	6.0k 1.8×	1.7k 1.0×	219	14.0k
Irene L. Andrulis Canada	53	4.3k 0.7×	2.9k 0.7×	2.5k 0.7×	5.4k 1.6×	1.8k 1.1×	243	10.7k
Melissa A. Troester United States	45	5.4k 0.9×	4.6k 1.2×	1.6k 0.5×	3.7k 1.1×	1.2k 0.7×	275	10.7k
Richard Elledge United States	48	6.2k 1.0×	4.3k 1.1×	2.5k 0.7×	2.8k 0.8×	1.9k 1.1×	102	10.0k
Gong Tang United States	34	4.8k 0.8×	6.1k 1.6×	1.6k 0.5×	2.6k 0.8×	1.5k 0.9×	112	10.0k
Beth Y. Karlan United States	69	6.4k 1.1×	3.9k 1.0×	4.4k 1.3×	8.0k 2.4×	1.6k 0.9×	336	18.9k
Claudine Isaacs United States	63	4.8k 0.8×	3.7k 0.9×	7.9k 2.3×	2.7k 0.8×	1.3k 0.7×	279	13.8k

Countries citing papers authored by Banu Arun

Since Specialization

Citations

This map shows the geographic impact of Banu Arun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Banu Arun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Banu Arun more than expected).

Fields of papers citing papers by Banu Arun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Banu Arun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Banu Arun. The network helps show where Banu Arun may publish in the future.

Co-authorship network of co-authors of Banu Arun

This figure shows the co-authorship network connecting the top 25 collaborators of Banu Arun. A scholar is included among the top collaborators of Banu Arun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Banu Arun. Banu Arun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arun, Banu, Fergus J. Couch, Jean Abraham, Nadine Tung, & Peter A. Fasching. (2024). BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. British Journal of Cancer. 131(9). 1400–1414. 16 indexed citations

Gutierrez‐Barrera, Angelica M., et al.. (2024). Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. Journal of Clinical Oncology. 42(18). 2186–2195. 1 indexed citations

Arun, Banu, et al.. (2024). What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open‐ended survey responses. Cancer. 130(22). 3926–3934.

Ricker, Charité, Banu Arun, Sara Pirzadeh‐Miller, et al.. (2024). Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. 20(10). 1308–1313. 3 indexed citations

Al‐Sukhun, Sana, Sarah Temin, Carlos H. Barrios, et al.. (2024). Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline. JCO Global Oncology. 10(10). e2300285–e2300285. 25 indexed citations

Daniels, Molly S., Ecaterina E. Dumbrava, Ying Yuan, et al.. (2023). Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. SHILAP Revista de lepidopterología. 7(1). 7–17. 1 indexed citations

Kumar, Tapsi, Fei Yang, Jeffrey T. Chang, et al.. (2022). Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clinical Cancer Research. 28(17). 3669–3676. 8 indexed citations

Liu, Xuan, Zhongqi Ge, Fei Yang, et al.. (2022). Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. npj Breast Cancer. 8(1). 64–64. 5 indexed citations

Chen, Minxing, Kristin Mattie, Generosa Grana, et al.. (2022). Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes. Cancer. 128(20). 3709–3717. 5 indexed citations

10.

Garber, Haven R., Akshara Singareeka Raghavendra, Wei Qiao, et al.. (2022). Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. npj Breast Cancer. 8(1). 46–46. 18 indexed citations

11.

Crew, Katherine D., Garnet L. Anderson, Dawn L. Hershman, et al.. (2019). Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prevention Research. 12(7). 481–490. 16 indexed citations

12.

Clifton, Katherine, Angelica M. Gutierrez‐Barrera, Junsheng Ma, et al.. (2018). Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Research and Treatment. 170(1). 101–109. 18 indexed citations

13.

Jiao, Shiping, Weiya Xia, Hirohito Yamaguchi, et al.. (2017). PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research. 23(14). 3711–3720. 768 indexed citations breakdown →

14.

Ratcliff, Chelsea G., Kathrin Milbury, Kavita D. Chandwani, et al.. (2016). Examining Mediators and Moderators of Yoga for Women With Breast Cancer Undergoing Radiotherapy. Integrative Cancer Therapies. 15(3). 250–262. 43 indexed citations

15.

Jain, Shalini, Xiao Wang, Chia‐Chi Chang, et al.. (2015). Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Research. 75(22). 4863–4875. 44 indexed citations

16.

Crew, Katherine D., Powel H. Brown, Heather Greenlee, et al.. (2012). Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer. Cancer Prevention Research. 5(9). 1144–1154. 76 indexed citations

17.

Zhang, Dongwei, Ana M. Tari, Uǧur Akar, et al.. (2010). Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer. Molecular Cancer Therapeutics. 9(11). 3090–3099. 17 indexed citations

18.

Arun, Banu, Kristen J. Vogel, Adriana López, et al.. (2009). High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prevention Research. 2(2). 122–127. 21 indexed citations

19.

Rivera, Edgardo, Christina Meyers, Morris D. Groves, et al.. (2006). Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 107(6). 1348–1354. 119 indexed citations

20.

Pusztai, Lajos, Mark Ayers, James Stec, et al.. (2003). Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.. PubMed. 9(7). 2406–15. 168 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact